MEDICAL Q&A: Cancer immunotherapy revolution is just beginning – Sarasota Herald-Tribune
|
MEDICAL Q&A: Cancer immunotherapy revolution is just beginning
Sarasota Herald-Tribune Q: Will the new methods of immunotherapy against cancer become the standard for treatment? A: In the fight against cancer, research is moving so fast that today’s breakthroughs can easily become tomorrow’s has-beens. Novartis recently got approval for … |
|
Syncona Leads $80 Million Round for Gene Therapy Firm Autolus
New York Times LONDON — Syncona has led a $80 million investment in Autolus, a company developing gene therapies to treat cancer, the healthcare investment group said on Tuesday. Gene-modifying immunotherapy is a new type of cancer treatment that harnesses the … |
FierceBiotech |
Eligo raises $20M to take bacteria-killing CRISPR drug into clinic
FierceBiotech The potential for CRISPR/Cas9 to enable targeted attacks on bacteria—sniper shots compared to antibiotic WMDs—has raised hopes the gene editing technology can address the antibiotic crisis. It has also attracted the attention of biotechs including … French Biotech Gets $20M to Treat the Microbiome with CRISPR NanobotsLabiotech.eu (blog) Khosla Ventures makes first investment in France, leads $18 million round in Eligo BioscienceVentureBeat Eligo Bioscience Secures $20 Million Series A from Khosla Ventures and Seventure to Bring Precision Medicine to the …PR Newswire (press release) |
The Guardian |
Immunotherapy has changed cancer medicine. But it’s no miracle cure
The Guardian She accepts my lengthy explanation but the next patient refuses, insisting that I either prescribe him immunotherapy or find someone that will. His liver is failing and his blood sugars are wildly abnormal – even if there were a trial available, he … |
|
Vivet’s First Gene Therapy Product, VTX 801 for Wilson’s Disease, Receives European and US Orphan Drug Designation
Business Wire (press release) PARIS–(BUSINESS WIRE)–Vivet Therapeutics, announced today that both the Food and Drug Administration (FDA) and the European Commission (EC) have granted Orphan Drug Designation (ODD) for Vivet’s lead gene therapy product, VTX-801, for the … |
The Business of Fashion |
BoF Exclusive | With Lab-Grown Leather, Modern Meadow Is Engineering a Fashion Revolution
The Business of Fashion “If we continue at the current pace, in principle in ten years it will be possible to write genetic code from scratch in quantities large enough to write entire synthetic genomes.” “Biology has undergone a huge revolution,” explains Forgacs. “Digital … |
WOAI |
The future of stem cell therapy in Texas
WOAI News 4 San Antonio also reached out to the University of Texas Health Science Center at San Antonio, in a statement , a spokesperson says, “Research of adult stem cells at UT Health San Antonio is preclinical (not in humans), and the institution is … |